Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Change in Receivables (2019 - 2024)

Revolution Medicines (RVMD) has 6 years of Change in Receivables data on record, last reported at -$1.3 million in Q1 2024.

  • For Q1 2024, Change in Receivables fell 84.96% year-over-year to -$1.3 million; the TTM value through Dec 2024 reached -$1.3 million, up 63.32%, while the annual FY2024 figure was -$1.3 million, 63.32% up from the prior year.
  • Change in Receivables reached -$1.3 million in Q1 2024 per RVMD's latest filing, down from $945000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $2.0 million in Q3 2020 and bottomed at -$2.9 million in Q4 2020.
  • Average Change in Receivables over 5 years is -$513941.2, with a median of -$678000.0 recorded in 2023.
  • The widest YoY moves for Change in Receivables: up 2975.0% in 2020, down 1264.32% in 2020.
  • A 5-year view of Change in Receivables shows it stood at -$2.9 million in 2020, then surged by 48.97% to -$1.5 million in 2021, then surged by 82.0% to -$267000.0 in 2022, then skyrocketed by 453.93% to $945000.0 in 2023, then tumbled by 232.7% to -$1.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were -$1.3 million in Q1 2024, $945000.0 in Q4 2023, and -$2.2 million in Q3 2023.